Prostate Cancer Prevention

The American Society of Clinical Oncology and the American Urological Association (ASCO and AUA) have issued a new guideline on the use of 5-alpha reductase inhibitors (5-ARI) for cancer chemoprevention. They found 15 randomized clinical trials that met their inclusion criteria. The main conclusion was that 5-ARI therapy during a 7-year period reduces the relative risk of developing prostate cancer by 25%. The absolute risk reduction however was only 1.4% which leads to about 71 persons needed to treat to prevent one cancer. Another way of looking at this result is that if 1000 men were followed over a period of 7 years, 59 would be expected to develop prostate cancer, and if they all took the 5-ARI, 45 would still develop cancer. This risk reduction is consistent with the result from the Prostate Cancer Prevention Trial which started in 1993 and was stopped in 2004 because of this same risk reduction. However, enthusiasm that should have arisen from this trial result, based on the 25% figure, was dramatically dampened by the suggestion that finasteride increased the risk of high-grade cancer. A majority (8 of 10) of members of the ASCO-AUA panel judged this higher observed incidence of high-grade cancer in the finasteride group to be due to confounding and thus not real. Finasteride is prescribed to relieve the symptoms of benign prostate hyperplasia (BPH—enlarged prostate) and 11 to 40 men experience side effects for every 1000 taking the drug. These include decreased sex drive and erectile dysfunction. The position taken by the ASCO-AUA is that men who are asymptomatic with a PSA equal to or less than 3.0 ng/mL may benefit from a discussion of the benefits of 5-ARIs vs. the risk of side effects. For men taking the drug for symptoms associated with BPH, the guidelines suggest that a discussion is in order to acquaint them with the possibility of increased risk of high-grade cancer, but as pointed out, the panel considered this risk unlikely, and thus given the need for the drug in the context of BPH, the potential cancer prevention is an added bonus. An additional problem with 5-ARI therapy is an approximate 50% drop in PSA which must then adjusted when applying cut-offs for triggering a biopsy. The panel did not take a position or a revised cut-off.

While obtaining a 25% risk reduction seems very appealing merely by popping a pill daily, individuals who would otherwise not take 5-ARIs need to seriously consider the very high number needed to treat to prevent one cancer. It is not hard to find physicians who regard 71 as too high to justify an intervention that is not totally risk free. There is also cost to consider. Finasteride can cost up to $60 U.S. per month.
Kramer BS, Hagerty KL, Justman S et al. Use of 5alpha-Reductase Inhibitors for Prostate Cancer Chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline. J Urol 2009 Apr;181(4):1642-57

GAMMA-E HELPS PREVENT PROSTATE CANCER
Several but not all follow-up studies on the impact of dietary or supplemental vitamin E on the incidence and progression of prostate cancer found a positive benefit, and there is an ongoing clinical trial in this regard involving the combination of vitamin E and selenium (the SELECT phase III trial). A recent study from the National Cancer Institute of the NIH and New York University has contributed to this subject. In this prospective study, Wright et al followed a cohort of almost 300,000 men who were cancer free at enrollment. Baseline supplemental and dietary intakes of alpha-, beta-, gamma- and delta-tocopherols were obtained from a questionnaire. At the end of 5 years follow-up over 10,000 prostate cancer cases were identified. Supplemental vitamin E (alpha-tocopherol) intake was not found to be associated with prostate cancer risk even at intakes equal to or greater than 800 IU/day. However, dietary gamma-tocopherol was found to be significantly and strongly inversely related to prostate cancer risk, with a 32% risk reduction when the highest vs. the lowest quintiles were compared. The median intake in the highest quintile was 20.8 mg/day with a range of 18.5 to 57.5. Furthermore, this beneficial effect was particularly evident among men with a low selenium intake. Gamma-tocopherol is the most commonly consumed form of vitamin E in the US diet. The authors list as major sources margarine, butter, salad dressings, fried potatoes, oils (mostly corn) cookies and brownies.

The potential anti-cancer properties of gamma-tocopherol appear to be under appreciated, given that most people appear to think of vitamin E only in terms of the common supplement, the alpha form. In a recent review titled Gamma-Tocopherol--An Underestimated Vitamin?, Wagner et al discuss a number of studies that relate to this question. One found a 5-fold reduction in prostate cancer risk for the highest vs. lowest quintiles of gamma-tocopherol intake. Another serum level study also found the same 5-fold reduction. However, a large trial involving U.S. physicians that also looked at serum levels failed to find a similar association. In addition, Wagner et al point out that gamma-tocopherol is more effective than alpha-tocopherol in inhibiting prostate cancer cells, reducing oxidative DNA damage and scavenging certain mutagens. Obviously, more studies are needed, but the evidence of the benefits of gamma-tocopherol in regard to prostate cancer is accumulating. In fact, it may occur to some readers that the SELECT trial may not be using the ideal form of vitamin E and that a negative outcome of this trial when it finally reports might well kill interest in vitamin E in general, including the gamma form.

Gamma-tocopherol is also available in supplements, generally as mixed tocopherols. Careful label reading is required since IU may be quoted (conversion 0.15 IU per mg) but it is common for only a total in IUs or milligrams for the beta, gamma and delta combined to be displayed. Products are available that contain 200 or more mg per capsule of the gamma form. Given that many individuals do not eat foods rich in the gamma form of vitamin E, supplements containing this form appear to be of interest.
Wright ME et al., 2007. Supplemental and dietary vitamin E intakes and risk of prostate cancer in a large prospective study. Cancer Epidemiol Biomarkers Prev. 16(6):1128-1135
Wagner KH, Kamal-Eldin A, Elmadfa I, 2004. Gamma-tocopherol--an underestimated vitamin? Ann Nutr Metab. 48(3):169-188
Weinstein SJ et al., 2007. Serum and dietary vitamin E in relation to prostate cancer risk. Cancer Epidemiol Biomarkers Prev. 16(6):1253-1259

TOMATO PRODUCTS AND ADVANCED PROSTATE CANCER
Another micronutrient that is frequently associated with prostate cancer is lycopene, the principal source of which is the tomato. Early studies suggested that both tomato products and circulating lycopene were associated with a reduced risk of prostate cancer. Jokes were even made about the merits in this context of eating lots of pizza. Bioavailability issues arose and it was found that products such as tomato paste were preferable to raw tomatoes. Two recent publications relate to this matter, one a report on a follow-up trial, the other a U.S. Food and Drug Administration (FDA) review done because processed food producers wished to make health claims for tomato products.

The follow-up trial was part of the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (PLCO). Participants were selected who underwent annual standardized screening for prostate cancer (PSA at entry and annually for 5 years and a digital rectal exam at entry and annually for 3 years). Thus this was a PSA-era study. No association was found between serum lycopene and total prostate cancer diagnosis risk or aggressive prostate cancer risk. The authors conclude that, consistent with other recent publications, these results suggest that lycopene or tomato- based regimens will not be effective in prostate cancer prevention.

The FDA report was based on a review of the literature and found "no credible evidence to support the association between lycopene intake and a reduced risk of prostate…cancer." However, they mention finding very limited evidence to support the association between tomato consumption and reduced risks of prostate cancer.

This latter report prompted Edward Giovannucci, a very well known epidemiologist from Harvard, to write an editorial trying to reconcile the FDA position with earlier studies that did indeed show benefit. His thesis is that the newer studies fail to find benefit from lycopene or tomato products because the studies are all done in the PSA era. Before the widespread use of PSA testing for screening purposes, most cancers that were diagnosed had progressed to a relatively advanced stage. What was being detected were manifestations of advanced disease such as metastasis and tumor growth outside the prostate itself. In the PSA era, most of the cancers detected would never have attracted clinical attention and include small, low-grade and indolent tumors. Thus studies of tomatoes and lycopene in the PSA era with the endpoint of cancer diagnosis are looking at the question of benefits during the early stages of disease development, whereas in earlier times, the potential benefit extended over a much longer period in the natural history of the disease. Consistent with this, Giovannucci points out that in the Health Professional's Follow-Up study (HPFS), the initial analysis of the data for the period 1986 to 1992 found an inverse association between tomato sauce intake and total prostate cancer incidence and the association was stronger for advanced cancer. Later analysis for the period 1992-1998 which was during the PSA era, the association was attenuated and weak but a strong association persisted for metastatic cancer. Combined data for these two periods gave a 66% risk reduction for = 2 servings per week to <1 serving per month. Finally an analysis of the data found no association between tomato sauce and the risk of diagnosis of organ-confined disease. Thus in the PSA era, the benefits of tomato sauce with regard to advanced cancer were swamped by the huge numbers of early non-advanced cases. In the HPFS study, Giovannucci comments that only strict criteria for aggressive behavior such as invasion into the seminal vesicle or metastasis were adequate to detect the association between tomato paste and an increased risk of fatal prostate cancer. He also points out that the FDA review was not designed to take into account these issues and the data needed are sparse.

These same observations apply to the PLCO study which was done in the PSA era. Thus it appears that tomatoes and lycopene provide benefit only in terms of influencing advanced cancer or offering benefit that is only significant when the exposure is over the full initiation and progression of the disease, as was the case in the early studies. It would appear that abandoning cooked tomato products like tomato sauce, and as well even supplemental lycopene, on the basis or recent studies is somewhat premature. Furthermore, it may be unrealistic to assume that studies will be carried out that might resolve the issues discussed, given the widespread PSA screening at present is the norm.
Peters U et al., 2007. Serum lycopene, other carotenoids, and prostate cancer risk: a nested case- control study in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Epidemiol Biomarkers Prev. 16(5):962-968
Kavanaugh CJ, Trumbo PR, Ellwood KC, 2007. The U.S. Food and Drug Administration's evidence-based review for qualified health claims: tomatoes, lycopene, and cancer. JNCI Cancer Spectrum. 99(14):1074- 1085

OMEGA-3 FATTY ACIDS AND PROSTATE CANCER PREVENTION
Dietary fatty acids have also been the subject of studies in the context of prostate cancer risk. Results have just been reported regarding these nutrients based on data collected in the Physician's Health Study. While this study had as its primary goal the evaluation of aspirin and beta-carotene in the primary prevention of heart disease and cancer, the cohort provided the opportunity for case-control studies of other questions. One such study has just reported which involved almost 15,000 apparently healthy men who provided blood samples in 1982. Blood fatty acid levels were measured for 476 men who developed prostate cancer during the 13-year follow- up and as well as for their matched controls. It was found that higher levels of the long-chain fatty acids mainly found in marine foods, and of linoleic acid, mainly found in non-hydrogenated vegetable oils, were associated with reduced risk of prostate cancer. In both, the relative risk reductions were about 40% when the highest quintile of serum level was compared to the lowest. The authors comment that in addition, their data suggest that the intake of polyunsaturated fatty acids appear unlikely to increase prostate cancer risk and that in addition, the intake of these fatty acids may in addition help prevent other common chronic diseases such as heart disease and diabetes. Thus these substances may have a broad implication in chronic disease prevention.
Chavarro JE et al., 2007. A prospective study of polyunsaturated fatty acid levels in blood and prostate cancer risk. Cancer Epidemiol Biomarkers Prev. 16(7):1364-1370

VITAMIN D AND PROSTATE CANCER
Although several studies have found vitamin D to be protective against both breast and colorectal cancers, the evidence for a protective effect in regard to prostate cancer is sparse and somewhat ambiguous. A recent study using data from the Physicians Health Study (14,916 participants) concluded that there was no significant difference in circulating vitamin D (1,25-dihydroxyvitamin D and 25-hydroxyvitamin D) between men with prostate cancer and the controls.

These results are surprising because of several recent studies that connect sun exposure to a reduced risk of prostate cancer. In one 528 prostate cancer patients and 442 basal cell carcinoma cases (a UV induced cancer) were examined for a correlation between cancer and sun exposure. Both groups were measured the same way as regards sun exposure. For those with the highest sun exposure, the risk of basal cell carcinoma was the highest, and for those with prostate cancer it was the lowest. In another study, increased sun exposure decreased prostate cancer mortality. In a study that looked at geographical distributions of UV intensity and prostate cancer mortality in the US, the expected variation with latitude was observed, i.e. those living in the higher latitudes had higher risk. Why this is not reflected in the Physicians Health Study as a more dramatic correlation between serum 25(OH)D and prostate cancer is not clear.